The in vitro activities of LFF571, a novel analog of GE2270A that inhibits bacterial growth by binding with high affinity for protein synthesis elongation factor Tu, fidaxomicin, and 10 other antimicrobial agents were determined against 50 strains of Clostridium difficile and 630 other anaerobic and aerobic organisms of intestinal origin. LFF571 possesses potent activity against C. difficile and most other Gram-positive anaerobes (MIC 90 , <0.25 g/ml), with the exception of bifidobacteria and lactobacilli. The MIC 90 s for aerobes, including enterococci, Staphylococcus aureus (as well as methicillin-resistant S. aureus [MRSA] isolates), Streptococcus pyogenes, and other streptococci were 0.06, 0.125, 2, and 8 g/ml, respectively. Comparatively, fidaxomicin showed variable activity against Gram-positive organisms: MIC 90 s against C. difficile, Clostridium perfringens, and Bifidobacterium spp. were 0.5, <0.015, and 0.125 g/ml, respectively, but >32 g/ml against Clostridium ramosum and Clostridium innocuum. MIC 90 for S. pyogenes and other streptococci was 16 and >32 g/ml, respectively. LFF571 and fidaxomicin were generally less active against Gram-negative anaerobes.
T oxigenic strains of Clostridium difficile are responsible for a spectrum of antibiotic-associated diarrheal diseases (C. difficile infection [CDI]) through elaboration of toxins A and B and other virulence factors (3, 9) . In recent years, a hypervirulent strain (NAP-1, 027, BI) has emerged causing more severe disease and higher mortality, especially in more susceptible elderly patients. It is also seen increasingly in outpatients, including pregnant and postpartum women and people without previous antibiotic exposure (24, 25) . Current antibiotic therapy for patients with CDI relies heavily on vancomycin or metronidazole, each of which has drawbacks, including treatment failure and frequent recurrence of disease. In addition, decreased susceptibility to metronidazole and vancomycin with emerging resistance to metronidazole (1, 2, 19) has potentiated the therapeutic dilemma. Only one new drug, fidaxomicin, has been developed during the past 30 years (17, 22) . Therefore, there is an unmet need for other new drugs for this serious illness.
The current theory of CDI pathogenesis (15) is that the use of antimicrobials leads to unintended changes in the normal gastrointestinal microbiota that leave patients vulnerable to the effects of toxigenic C. difficile. Several strategies have emerged for the prevention and treatment of CDI, which include the use of probiotics (14) , the restoration of the protective fecal microbiota (fecal biotherapy) (29) , and the development of new agents that are less disruptive to the normal microbiota, especially the anaerobic component.
The thiopeptide LFF571 is a novel analog of the natural product GE2270 A, both of which inhibit bacterial growth by binding with high affinity for protein synthesis elongation factor Tu (10) . GE2770 A has demonstrated excellent activity against a variety of Gram-positive organisms (16) . In a study characterizing the mechanism of activity of LFF571, there was no evidence of inhibition of other biosynthetic pathways or disruption of bacterial membranes (20) . LFF571 inhibits C. difficile in vitro and has proved more efficacious than vancomycin in an experimental hamster model of primary and relapsing C. difficile infection (26) .
In order to fully assess LFF571's effect on fecal microbiota, we compared its in vitro activity with that of fidaxomicin, which has been shown to have a lesser effect on the levels of Bacteroides species and the gut microbiota than vancomycin and with 10 other antimicrobial agents against 50 strains of C. difficile and 630 other intestinal aerobic and anaerobic bacterial isolates representing 25 genera and 48 species.
MATERIALS AND METHODS
LFF571 was prepared by Novartis (Basel, Switzerland). Fidaxomicin (lipiarmycin A3) was prepared by fermentation of Catellatospora sp. Bp3323-81 at Novartis and supplied as a reference powder. Other laboratory reference powders were obtained from their manufacturer, USP or Sigma (St. Louis, MO), reconstituted according to the manufacturers' instructions, and stored at Ϫ70°C. On the day of testing, a tube of each stock solution was thawed and diluted according to the instructions in CLSI M7 and M11 documents (7, 8) .
C. difficile strains were recovered from toxin-positive fecal specimens. The restriction endonuclease analysis (REA) groups included 16 BI, 6 Y, 4 J, 2 G, 2 CF, 1 BK, 1 Z, and 20 nonspecific strains. REA typing was conducted at Dale Gerding's laboratory using the method of Clabots (6) . Other organisms representing 25 different genera and 48 species were cultured from clinical samples and identified by standard methods or by partial sequencing of the 16S rRNA gene and stored in 20% skim milk at Ϫ70°C (18, 23, 28) . Strains were taken from the freezer and subcultured at least twice on supplemented brucella agar for anaerobes and on blood Trypticase soy agar for aerobes to ensure good growth. Anaerobes were incubated for 48 h and aerobes for 24 h prior to testing. Inocula were prepared by direct suspensions of cells into brucella broth for anaerobes or cation-adjusted Mueller-Hinton broth (CAMHB) for aerobes.
Quality control strains included Clostridium difficile ATCC 700057, Bacteroides fragilis ATCC 25285, Staphylococcus aureus ATCC 29213, Enterococcus faecalis ATCC 29212, and Escherichia coli ATCC 25922 (for the comparator drugs).
For anaerobic organisms, supplemented brucella agar deeps were ob-tained from Anaerobe Systems (Morgan Hill, CA). Defibrinated sheep blood (Hardy Diagnostics, Santa Maria, CA) was frozen and thawed to produce laked blood. On the day of testing, laked blood and the antimicrobial agents were added to the tubes of molten agar before pouring the agar dilution plates. The strains were applied to the plates using a Steers multipronged inoculator for a final concentration of approximately 10 5 CFU/spot. After 44 h of incubation at 36°C in the anaerobic chamber incubator, the plates were examined for growth and the MICs interpreted (7) . MIC panels for testing aerobic organisms were prepared in-house using the Quick-Spense apparatus (Sandy Spring Instrument Co. Inc., Germantown, MD) at double antimicrobial strength, 50 l/well, using CAMHB, and stored at Ϫ70°C until used. Tests for Streptococcus, Lactococcus, Leuconostoc, Pediococcus, and Aerococcus strains were supplemented with 2.5% lysed horse blood (LHB; Hardy Diagnostics) by adding 5% LHB to the inoculum tube and then adding 50 l of inoculum to each well for a final concentration of ϳ5ϫ 10 5 CFU/ml. Panels were incubated for 20 h at 35°C before reading and interpreting the MICs (8) . Table 1 summarizes and compares the activities of LFF571 and fidaxomicin against the major groups of organisms. Table 2 shows a Anaerobic organisms were tested by the agar dilution method; aerobic organisms were tested by broth microdilution (7, 8) . a Anaerobic organisms were tested by the agar dilution method; aerobic organisms were tested by broth microdilution (7, 8) . e Peptostreptococcus anaerobius (12) , P. stomatis (8) .
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f Prevotella melaninogenica (15) , P. denticola (6) . g Fusobacterium mortiferum (10), F. varium (10) . h Aerococcus sanguinicola (2), A. viridans (8) .
i Streptococcus constellatus (16) , S. intermedius (10) . 
